COPP is a
chemotherapy regimen for treatment of
Hodgkin disease, consisting of concurrent treatment with
(C)yclophosphamide,
(O)ncovin,
(P)rocarbazine and
(P)rednisone.
It contains less procarbazine than
MOPP (procarbazine is given only for 10 days in cycle instead of 14), and the very toxic
mechlorethamine, which is prone to giving severe
neutropenia
Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood. Neutrophils make up the majority of circulating white blood cells and serve as the primary defense against infections by destroying bacteria ...
and to severely heighten the risk of secondary malignancies, is changed to less toxic cyclophosphamide, which is more safe to the progenitor stem cells (thus, less neutropenia) and less prone to give late secondary malignancies.
Thus, the COPP regimen is considered safer and less toxic than MOPP. But it offsets with somewhat less efficacy, especially in advanced-stage Hodgkin disease.
Nevertheless, both the COPP and the MOPP are now supplanted by
ABVD, which is less toxic and more effective than either COPP or MOPP.
Dosage
References
{{DEFAULTSORT:Copp
Chemotherapy regimens used in lymphoma